

Cost – utility analysis of a medication adherence management service alongside a cluster randomized control trial in community pharmacy

SUPPLEMENTARY INFORMATION

CHEERS Checklist

Items to include when reporting economic evaluations of health interventions

Section / item	Item n°	Recommendation	Reported on page n° / section
Title and abstract			
Title	1	Identify the study as an economic evaluation or use more specific terms such as “cost-effectiveness analysis”, and describe the interventions compared.	Line 3 to 5; page 1; section <i>Title</i>
Abstract	2	Provide a structured summary of objectives, perspective, setting, methods (including study design and inputs), results (including base case and uncertainty analyses), and conclusions	Line 37 to 61; page 3; section <i>Abstract</i>
Introduction			
Background and objectives	3	Provide an explicit statement of the broader context for the study. Present the study question and its relevance for health policy or practice decisions.	Line 67 to 109; page 5 and 6; section <i>Introduction</i>

Methods			
Target population and Subgroup	4	Describe characteristics of the base case population and subgroups analysed, including why they were chosen	Line 120 to 126; page 7; section <i>Study design and characteristics</i>
Setting and location	5	State relevant aspects of the system(s) in which the decision(s) need(s) to be made.	Line 120 to 126; page 7; section <i>Study design and characteristics</i>
Study perspective	6	Describe the perspective of the study and relate this to the costs being evaluated.	- Line 45-46; page 3; section <i>Abstract</i> . - Line 114; page 6; section <i>Economic evaluation description</i> - Table 1. - Line 149 to 191; page 8 to 10; section <i>Costs</i>
Comparators	7	Describe the interventions or strategies being compared and state why they were chosen.	- Line 129 to 139; page 7; section <i>Intervention Group</i> - Line 141 to 143; page 8; section <i>Control Group</i> - Figure 1
Time horizon	8	State the time horizon(s) over which costs and consequences are being evaluated and say why appropriate.	- Line 42; page 3; section <i>Abstract</i> . - Line 114 to 118; page 6-7; section <i>Economic evaluation description</i> - Table 1

Discount rate	9	Report the choice of discount rate(s) used for costs and outcomes and say why appropriate.	- Line 117; page 7; section <i>Economic evaluation description</i> - Table 1
Choice of health Outcomes	10	Describe what outcomes were used as the measure(s) of benefit in the evaluation and their relevance for the type of analysis performed.	Line 207 to 219; page 11 and 11; section <i>Cost-Utility analysis</i>
Measurement of effectiveness	11	<i>Single study-based estimates:</i> Describe fully the design features of the single effectiveness study and why the single study was a sufficient source of clinical effectiveness data.	Line 193 to 205; page 10; section <i>Utility from the Health-Related Quality of Life (HR-QoL)</i>
Measurement and valuation of preference based outcomes	12	If applicable, describe the population and methods used to elicit preferences for outcomes.	Line 193 to 205; page 10; section <i>Utility from the Health-Related Quality of Life (HR-QoL)</i>
Estimating resources and cost	13a	<i>Single study-based economic evaluation:</i> Describe approaches used to estimate resource use associated with the alternative interventions. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs.	Line 149 to 191; page 8 to 10; section <i>Costs</i>

Currency, price date, and conversion	14	Report the dates of the estimated resource quantities and unit costs. Describe methods for adjusting estimated unit costs to the year of reported costs if necessary. Describe methods for converting costs into a common currency base and the exchange rate.	Line 149 to 191; page 8 to 10; section <i>Costs</i>
Choice of model	15	Describe and give reasons for the specific type of decision analytical model used. Providing a figure to show model structure is strongly recommended.	Line 207 to 219; page 10 and 11; section <i>Cost-Utility analysis</i>
Assumptions	16	Describe all structural or other assumptions underpinning the decision-analytical model.	N/A
Analytical methods	17	Describe all analytical methods supporting the evaluation. This could include methods for dealing with skewed, missing, or censored data; extrapolation methods; methods for pooling data; approaches to validate or make adjustments (such as half cycle corrections) to a model; and methods for handling population heterogeneity and uncertainty.	Line 207 to 219; page 10 and 11; section <i>Cost-Utility analysis</i>
Results			
Study parameters	18	Report the values, ranges, references, and, if used, probability distributions for all parameters. Report reasons or sources for distributions used to represent uncertainty where appropriate. Providing a table to show the input values is strongly recommended.	- Line 229 to 273; page 11 to 13; sections <i>Participants, Costs and Utility from the Health-Related Quality of Life (HR-QoL)</i> - Tables 2, 3 and 4

Incremental costs and Outcomes	19	For each intervention, report mean values for the main categories of estimated costs and outcomes of interest, as well as mean differences between the comparator groups. If applicable, report incremental cost-effectiveness ratios.	- Line 275 to 287; page 13 and 14; section <i>Cost-Utility analysis</i> - Table 5 - Figures 2 and 3.
Characterising Uncertainty	20a	<i>Single study-based economic evaluation:</i> Describe the effects of sampling uncertainty for the estimated incremental cost and incremental effectiveness parameters, together with the impact of methodological assumptions (such as discount rate, study perspective).	- Line 275 to 287; page 13 and 14; section <i>Cost-Utility analysis</i> - Table 5 - Figures 2 and 3.
Characterising heterogeneity	21	If applicable, report differences in costs, outcomes, or cost-effectiveness that can be explained by variations between subgroups of patients with different baseline characteristics or other observed variability in effects that are not reducible by more information.	N/A
Discussion			
Study findings, limitations, generalisability, and current knowledge	22	Summarise key study findings and describe how they support the conclusions reached. Discuss limitations and the generalisability of the findings and how the findings fit with current knowledge.	- Line 289 to 388; page 14 to 17; section <i>Discussion and Limitations and strengths</i>

Other			
Source of funding	23	Describe how the study was funded and the role of the funder in the identification, design, conduct, and reporting of the analysis. Describe other non-monetary sources of support.	Line 411 to 414; page 18 and 19; section <i>Disclosure</i>
Conflicts of interest	24	Describe any potential for conflict of interest of study contributors in accordance with journal policy. In the absence of a journal policy, we recommend authors comply with International Committee of Medical Journal Editors recommendations.	Line 410; page 18; section <i>Disclosure</i>